CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Trial Details
- NCT ID
- NCT06690775
- Phase
- PHASE2
- Sponsor
- TORL Biotherapeutics, LLC
- Status
- RECRUITING
- Cancer Type
- Ovarian Cancer
- Interventions
- TORL-1-23
- Pegfilgrastim (drug)
- Locations (sample)
- Phoenix, Arizona, United States|33.44838,-112.07404
- Tucson, Arizona, United States|32.22174,-110.92648
- Duarte, California, United States|34.13945,-117.97729
- Fullerton, California, United States|33.87029,-117.92534
- Los Angeles, California, United States|34.05223,-118.24368
Key Eligibility Criteria
- Participants are eligible to be included in the study only if all the following criteria apply:
- Females ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the informed c…
- Participants must sign the informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (…
- Disease Type:
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →